Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder

Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder: A Target Trial Emulation Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07032337

Enrollment

2985

Registered

2025-06-23

Start date

2011-01-01

Completion date

2022-12-31

Last updated

2025-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Keywords

immunosuppressive therapies, azathioprine, mycophenolate mofetil, rituximab, elderly

Brief summary

Newly diagnosed NMOSD patients

Detailed description

From 2011 to 2022, newly diagnosed NMOSD patients who had not previously claimed NMOSD. Exclusion criteria were history of cancer or had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* From 2011 to 2022, newly diagnosed NMOSD patients..

Exclusion criteria

* Patients had a history of cancer * Patients had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

Design outcomes

Primary

Measure	Time frame	Description
Relapse	1 year	Relapses were identified when patients were treated with one of the following interventions: intravenous steroids, immunoglobulin therapy, or plasma exchange.

Secondary

Measure	Time frame	Description
Safety outcomes	6 months after start of ISTs	Incidence of serious infection, fracture, cancer, myocardial infarction, stroke, depression, anxiety, dementia, and Parkinson's disease which defined as presence of ICD-10 codes.

Outcome results